Prevention and control of influenza in children: AAP recommendation

Paediatrics
Influenza is an important cause of respiratory illness in children and can result in substantial morbidity, including severe or fatal complications. Children younger than 5 years and those with certain underlying medical conditions are particularly vulnerable to influenza-associated complications. Furthermore, children play a pivotal role in transmitting influenza virus infection to household members and other close contacts. Annual influenza vaccination reduces the disease burden directly in children and indirectly among household members, close contacts, and community members of all ages. By reducing respiratory illnesses, vaccination also helps preserve healthcare capacity, particularly when multiple respiratory viruses are circulating. The American Academy of Pediatrics (AAP) emphasizes annual vaccination, appropriate diagnostic testing, antiviral treatment, and effective implementation strategies to prevent and control influenza in children[1]:Influenza vaccination recommendationsAnnual influenza vaccination is recommended for all individuals aged 6 months and older during every influenza seasonAny licensed influenza vaccine appropriate for age and health status may be administered, including standard-dose inactivated influenza vaccine (SD-IIV), cell culture-based inactivated influenza vaccine (ccIIV), recombinant influenza vaccine (RIV), and live attenuated influenza vaccine (LAIV)LAIV should not be administered to immunocompromised individuals or those with certain chronic medical conditionsThe number of influenza vaccine doses recommended for children remains unchanged for the 2026–2027 influenza season and depends on the child's age at first-dose administration and previous influenza vaccination history. Doses administered up to 4 days before the minimum recommended interval are considered validWhen two doses are recommended during the same influenza season, the formulations do not need to be identical. A combination of IIV (SD-IIV or ccIIV), RIV, and LAIV may be administered if appropriate for age and health statusInfluenza vaccination should be offered as soon as the vaccine becomes available, particularly to children requiring two doses. The recommended dose or doses should ideally be administered by the end of October to ensure protection before the influenza seasonRecommendations for immunocompromised childrenAge-appropriate IIV or RIV should be administered to moderately to severely immunocompromised children before the start of the influenza season whenever possibleChildren with malignancies receiving chemotherapy should receive IIV or RIV at least 2 weeks before cytotoxic chemotherapy whenever possibleChildren receiving immunosuppressive treatment for underlying autoimmune or autoinflammatory conditions should receive IIV or RIV at least 2 weeks before starting these therapies whenever possibleChildren scheduled to receive anti-B-cell therapies, including Rituximab or Alemtuzumab, should receive IIV or RIV at least 2 weeks before treatment initiation whenever possibleFollowing B-lymphocyte-depleting therapy, IIV or RIV should be considered 3-6 months after the last dose. Earlier vaccination may be considered if influenza is circulating in the communityFollowing CD19-targeted chimeric antigen receptor T-lymphocyte (CAR-T) infusion, IIV or RIV should be considered 3-6 months after treatment in patients who are in remission and do not require additional intensive chemotherapy or hematopoietic cell transplantation (HCT)IIV or RIV should be considered starting at least 3 months after HCTIn pediatric HCT recipients aged 3-17 years during the first year after transplantation, two doses of high-dose IIV administered 28-42 days apart may be considered, recognizing that high-dose IIV is not approved for use in childrenPediatric solid organ transplant (SOT) recipients aged 6 months through 17 years should receive IIV or RIV at least 1 month after transplantationFor SOT recipients aged 18 years and older receiving immunosuppressive medications, high-dose (HD) or adjuvanted inactivated influenza vaccine (aIIV) are acceptable optionsChildren living with HIV infection should receive age-appropriate IIV or RIV before the start of the influenza season whenever possibleHousehold members and close contacts of immunocompromised patients should remain up to date with influenza vaccinationAdditional recommendations for pregnancy, breastfeeding, and travelInfluenza vaccination is recommended during pregnancy to benefit both the pregnant individual and the infant. IIV, ccIIV, or RIV may be administered at any time during pregnancyPregnant individuals who have not received influenza vaccination during pregnancy should receive the vaccine before hospital discharge. Those who decline vaccination during hospitalization should be encouraged to discuss vaccination with their obstetrician, primary care physician, nurse midwife, or another qualified healthcare professionalInfluenza vaccination of breastfeeding individuals is recommended because it provides protection to both the parent and infant and is considered safeIndividuals traveling to tropical regions, on cruise ships, to the Southern Hemisphere, or to other locations where influenza may be circulating between April and September should consider seasonal influenza vaccination at least 2 weeks before departure if they were not vaccinated during the preceding fall or winter and vaccine is availableRecommendations for healthcare personnelAnnual influenza vaccination of healthcare personnel is recommended as a condition of employment and is considered a crucial strategy for reducing healthcare-associated influenza virus infectionsInfluenza vaccine implementation and advocacyEvidence-based strategies should be implemented to promote influenza vaccination among all children, particularly those younger than 5 years, children in other high-risk groups, and their contacts, unless vaccination is contraindicatedCommunity members should be involved in developing culturally relevant vaccination strategies to address disparities in influenza vaccinationStrategies for communicating with families about vaccines and promoting vaccine confidence should be implementedAccess to vaccination should be improved through schools, pharmacies, hospitals, and other nontraditional settings. However, vaccination in the medical home is preferred for young children to facilitate well-child care, preventive screening, anticipatory guidance, and other important childhood vaccinationsFor patients and families facing resource constraints that would prevent vaccination in the medical home, at-home administration of LAIV may be an alternative for eligible individuals aged 2-49 yearsWhen influenza vaccination is administered outside the medical home, documentation should be provided to patients, shared with the medical home, and submitted to the required state or regional immunization information systems (IISs)Pediatric practices may consider offering influenza vaccination to family members and close contacts of childrenPublic and private payers should provide adequate reimbursement for influenza vaccine administration in pediatric populations, update policies to cover doses administered in July and August, and eliminate patient-responsibility cost barriers to vaccinationDisparities in influenza vaccine supply between privately insured patients and those eligible for the Vaccines for Children (VFC) program should be eliminated. Pediatricians and other primary care pediatric providers should be aware of policies permitting borrowing between VFC and non-VFC vaccine supplies and use these policies to address availability disparities where permittedInformation about influenza vaccines and vaccination clinics should be provided to eligible children and their families in their preferred languageInfluenza vaccine contraindications and precautionsProduct-specific contraindications and precautions should be considered when selecting an influenza vaccineA history of severe allergic reaction, including anaphylaxis, to any influenza vaccine generally constitutes a contraindication to future influenza vaccination. Children who experience a severe allergic reaction following influenza vaccination should undergo evaluation by an allergist to identify the responsible vaccine component and determine whether future vaccination is appropriateChildren with gelatin allergy should receive IIV or age-appropriate RIV instead of LAIV. An overlap between gelatin allergy and alpha-gal allergy has been reportedChildren with egg allergy of any severity, including anaphylaxis, may receive any influenza vaccine without additional precautions beyond those recommended for all vaccinesChildren with acute moderate or severe illness may receive influenza vaccination once their acute illness has improved. Strategies such as scheduling a return visit, sending reminder messages, or administering the vaccine before hospital discharge should be implemented to support timely vaccination. Children with mild illness, including low-grade fever, should still be vaccinatedA history of seizures or febrile seizures is not a precaution or contraindication to influenza vaccinationInfluenza testing recommendationsInfluenza testing should be performed in children presenting with signs and symptoms of influenza when the results are expected to influence clinical management, including decisions regarding antiviral treatment, avoidance of antibiotic therapy, additional diagnostic investigations, initiation of infection prevention and control measures, or differentiation from other respiratory viruses with similar symptomsHospitalized children with signs and symptoms of influenza should undergo nucleic acid amplification testing with high sensitivity and specificity, such as reverse transcriptase-polymerase chain reaction (RT-PCR), when influenza is circulating in the community. Testing should inform treatment and infection control practicesAt-home influenza tests are available for children as young as 6 months; however, data on their use in pediatric patients are limited. Results should be interpreted according to test sensitivity and specificity, community influenza prevalence, the presence and duration of compatible signs and symptoms, and individual risk factors and comorbiditiesTesting for avian influenza, including influenza A (H5N1), or other novel influenza strains should be performed under the direction of public health authoritiesPediatricians and other pediatric healthcare professionals should consider asking about exposure to sick or dead animals, particularly wild birds, poultry, and dairy cows, to determine the need for avian influenza testingAntiviral treatment and chemoprophylaxisAntiviral medications are an important adjunct to influenza prevention and control but are not a substitute for influenza vaccination. The role of antiviral medications in preventing and treating influenza in children depends on illness severity and individual risk factors. Although the greatest benefit is generally observed when treatment is initiated within 48 hours of symptom onset, antiviral medications may also be offered beyond 48 hours in certain cases.Summary of antiviral treatment and chemoprophylaxis recommendationsCategoryPatient group/indicationsTimingRecommendationTreatment of symptomatic diseaseHospitalized children; children with severe, complicated, or progressive illness; children at higher risk for complicationsNo time limit for initiation; ideally as soon as possible after symptom onsetRecommend treatment Children with household contacts at high risk because of underlying medical conditions; children with household contacts younger than 6 monthsAs early as possibleConsider treatment Children with mild-to-moderate influenza-like symptoms without other risk factorsWithin 48 hours of symptom onsetConsider treatmentChemoprophylaxis for asymptomatic exposuresUnvaccinated or incompletely vaccinated children at high…